TY - JOUR
T1 - Elucidation of the effect of added fines on the performance of dry powder inhalation formulations
AU - Stankovic-Brandl, Milica
AU - Radivojev, Snezana
AU - Sailer, Pia
AU - Penz, Franz Karl
AU - Paudel, Amrit
N1 - Funding Information:
The Research Center Pharmaceutical Engineering (RCPE) is funded within the framework of COMET - Competence Centers for Excellent Technologies by BMK, BMDW, Land Steiermark, and SFG. The COMET program is managed by the FFG.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/12/15
Y1 - 2022/12/15
N2 - Dry powder inhalers (DPIs) are regularly used to treat respiratory diseases. Adding extrinsic fine excipient particles to the blend of active pharmaceutical ingredient (API) and carrier is an established strategy to improve aerosolization efficiency during pulmonary drug delivery. Different amounts and grades of lactose fines may, however, compromise the flowability and downstream processing of the material. Further, given the particle size of the inhaled fine particles (<5.5 µm), also deposition of lactose fines to different lung regions following inhalation cannot be excluded. This study aimed to investigate the impact of commercially available extrinsic lactose fine materials produced using different milling parameters, on physicochemical properties and aerosolization performance of ternary blends, as a factor of time and storage conditions. Further, for the first time, it was attempted to elucidate the effect that the amount of present fines has on the dissolution of the model API from the ternary blends exposed to different storage conditions. We showed that rheological behavior was impacted when a higher amount of fines was present, and this effect was further enhanced by storage at high relative humidity. The aerosolization efficiency was vastly improved with increasing content of fines. Still, initial data indicated that the dissolution of the poorly soluble API was retarded when more fines were present in blends.
AB - Dry powder inhalers (DPIs) are regularly used to treat respiratory diseases. Adding extrinsic fine excipient particles to the blend of active pharmaceutical ingredient (API) and carrier is an established strategy to improve aerosolization efficiency during pulmonary drug delivery. Different amounts and grades of lactose fines may, however, compromise the flowability and downstream processing of the material. Further, given the particle size of the inhaled fine particles (<5.5 µm), also deposition of lactose fines to different lung regions following inhalation cannot be excluded. This study aimed to investigate the impact of commercially available extrinsic lactose fine materials produced using different milling parameters, on physicochemical properties and aerosolization performance of ternary blends, as a factor of time and storage conditions. Further, for the first time, it was attempted to elucidate the effect that the amount of present fines has on the dissolution of the model API from the ternary blends exposed to different storage conditions. We showed that rheological behavior was impacted when a higher amount of fines was present, and this effect was further enhanced by storage at high relative humidity. The aerosolization efficiency was vastly improved with increasing content of fines. Still, initial data indicated that the dissolution of the poorly soluble API was retarded when more fines were present in blends.
KW - Aerosolization
KW - Budesonide
KW - Dissolution
KW - DPI
KW - Fines
KW - Lactose
UR - http://www.scopus.com/inward/record.url?scp=85141439393&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2022.122359
DO - 10.1016/j.ijpharm.2022.122359
M3 - Article
C2 - 36332830
AN - SCOPUS:85141439393
SN - 0378-5173
VL - 629
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 122359
ER -